Curis, Inc. (NASDAQ:CRIS – Free Report) – Analysts at HC Wainwright increased their Q2 2026 earnings estimates for Curis in a report issued on Friday, July 24th. HC Wainwright analyst S. Nik now expects that the biotechnology company will post earnings of ($5.70) per share for the quarter, up from their previous forecast of ($5.80). HC Wainwright has a “Buy” rating and a $43.00 price target on the stock. The consensus estimate for Curis’ current full-year earnings is ($25.50) per share. HC Wainwright also issued estimates for Curis’ Q3 2026 earnings at ($5.87) EPS, Q4 2026 earnings at ($6.04) EPS, FY2026 earnings at ($33.78) EPS and FY2027 earnings at ($26.53) EPS.
Curis (NASDAQ:CRIS – Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($25.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.53) by ($18.47).
Check Out Our Latest Stock Report on CRIS
Curis Price Performance
Shares of NASDAQ:CRIS opened at $4.69 on Tuesday. Curis has a 1 year low of $3.61 and a 1 year high of $39.00. The business’s 50-day moving average is $7.59 and its 200-day moving average is $13.11. The company has a market capitalization of $9.15 million, a price-to-earnings ratio of -0.20 and a beta of 3.08.
Institutional Trading of Curis
Several large investors have recently made changes to their positions in the company. Renaissance Technologies LLC increased its position in Curis by 52.2% in the 1st quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock valued at $201,000 after buying an additional 125,823 shares in the last quarter. Focused Wealth Management Inc boosted its holdings in Curis by 83.4% in the first quarter. Focused Wealth Management Inc now owns 109,746 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 49,900 shares in the last quarter. XTX Topco Ltd bought a new position in Curis in the fourth quarter worth approximately $26,000. Squarepoint Ops LLC grew its stake in Curis by 46.2% in the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 27,343 shares during the period. Finally, Jane Street Group LLC grew its stake in Curis by 71.8% in the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 10,586 shares during the period. 29.97% of the stock is currently owned by institutional investors and hedge funds.
Curis Company Profile
Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.
Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.
Featured Articles
- Five stocks we like better than Curis
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
